Health & Biotech
Dr Boreham’s Crucible: This cancer-tackling biotech might just have a fighting chance
Health Check: Percheron board addresses shareholders after failed phase 2b trial
The storied Australian drug developer turning his skills to funds management
Health Check: Local biotech starred in 2024, but the rising tide did not lift all boats
Health Check: With yet another customer win, Pro Medicus storms to 2024 finish line with a wet sail
ASX healthcare 2024 winners and losers, plus what’s next for 2025
Dr Boreham’s Crucible: Can this cancer drug hopeful meet a desperate unmet need?
Recruitment on track for Dimerix’s global kidney disease trial
Health Check: Telix CEO gets pay bump as company files for US kidney imaging approval
Biocurious: Behind Race Oncology’s quest to prevent chemo from being worse than the disease
Stocking stuffers: Morgans’ top ASX health picks for 2025
Scott Power: Which stock fell off its perch on poor trial results this week?
Lumos starts ‘pivotal clinical study’ in US for point-of-care respiratory test
FDA pre-approval inspection of EBR’s WiSE CRT system set for early January
Orthocell files FDA application to sell nerve-repair product in the US
LTR Pharma inks deal with men’s health provider for ED therapy
BlinkLab gains FDA support for trial of app aiding autism diagnosis
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.
